Specificities of platelet autoantibodies and platelet activation in lupus anticoagulant patients: A relation to their history of thromboembolic disease

Lupus

Volumn 15, Issue 8, 2006, Pages 507-514

  Schallmoser, K ^a,b   Rosin, C ^a   Vormittag, R ^a   Brunner, M ^a   Dunkler, D ^a   Pabinger, I ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Lupus anticoagulant; Platelet activation; Platelet autoantibodies; Thromboembolic disease

Indexed keywords

FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IX; LUPUS ANTICOAGULANT; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CONTROLLED STUDY; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CHILD; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MIDDLE AGED; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; RANDOM ALLOCATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 33747882062     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2341oa     Document Type: Article

References (36)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
2. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698.
3. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
4. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
5. Out HJ, de Groot PG, van Vliet M, de Gast GC, Nieuwenhuis HK, Derksen RH. Antibodies to platelets in patients with anti-phospholipid antibodies. Blood 1991; 77: 2655-2659.
6. Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1994; 71: 571-575.
7. Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997; 98: 873-879.
8. Panzer S, Pabinger I, Gschwandtner ME, Mayr WR, Hutter D. Lupus anticoagulants: strong association with the major histocompatibility complex class II and platelet antibodies. Br J Haematol 1997; 98: 342-345.
9. Panzer S, Gschwandtner ME, Hutter D, Spitzauer S, Pabinger I. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Ann Hematol 1997; 74: 239-242.
10. Niessner H, Clemetson KJ, Panzer S, Mueller-Eckhardt C, Santoso S, Bettelheim P. Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies. Blood 1986; 68: 571-576.
11. Yanabu M, Nomura S, Fukuroi T et al. Platelet activation induced by an antiplatelet autoantibody against CD9 antigen and its inhibition by another autoantibody in immune thrombocytopenic purpura. Br J Haematol 1993; 84: 694-701.
12. Olsson A, Andersson PO, Tengborn L, Wadenvik H. Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function. Thromb Res 2002; 107: 135-139.
13. Kekomaki R. Platelet function and immune response. J Pediatr Hematol Oncol 2003; 25 (Suppl 1): S19-23.
14. Boylan B, Chen H, Rathore V et al. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 2004; 104: 1350-1355.
15. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-459.
16. Shi W, Chong BH, Chesterman CN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255-1262.
17. Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88: 878-880.
18. Macchi L, Rispa P, Clofent-Sanchez G et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98: 336-341.
19. Tan EM, Cohen AS, Fries JF et al. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
20. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
21. Zoghlami-Rintelen C, Vormittag R, Sailer T et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-1165.
22. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726.
23. Kiefel V, Santoso S, Mueller-Eckhardt C. Serological, biochemical, and molecular aspects of platelet autoantigens. Semin Hematol 1992; 29: 26-33.
24. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83: 1024-1032.
25. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005; 14: 499-504.
26. Karpatkin S, Garg SK, Siskind GW. Autoimmune thrombocytopenic purpura and the compensated thrombocytolytic state. Am J Med 1971; 51: 1-4.
27. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114.
28. Michelson AD, Barnard MR, Hechtman HB et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-11882.
29. Solanilla A, Pasquet JM, Viallard JF et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105: 215-218.
30. Schallmoser K, Rosin C, Knittelfelder R et al. The FcγRIIa polymorphism R/H131, autoantibodies against the platelet receptors GPIbα and FcγRIIa and a risk for thromboembolism in lupus anticoagulant patients. Thromb Haemost 2005; 93: 544-548.
31. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem 1988; 104: 628-632.
32. Conway EM, Van de Wouwer M, Pollefeyt S et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565-577.
33. Esmon CT. Platelets are anticoagulants? Blood 2003; 102: 3.
34. Slungaard A, Fernandez JA, Griffin JH et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003; 102: 146-151.
35. De Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005; 3: 1854-1860.
36. Pennings MTT, Derksen RHWM, van Lummel M et al. Platelet adhesion to dimeric beta2-glycoprotein-I under conditions of flow is mediated by glycoprotein Ibα. J Thromb Haemost 2005; 3(Suppl 1): OR256.